Clinical trials: Neoplasms, Hematopoietic
Hematopoietic Neoplasm
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
Primary Objective: To evaluate the efficacy of daily oral doses of 400 mg or 500 mg of SAR302503 (Investigational Medicinal Product, IMP) compared to placebo in the reduction of spleen volume as determined by magnetic resonance…
- Trial name
- JAKARTA (NCT01437787)
- Testing
- SAR302503
- Where
- 101 sites in United States, Australia and 23 more
- Volunteers
- 289 people
- Sponsor
- Bristol-Myers Squibb
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
The purpose of this study is to determine whether a repeat dose administration of ATIR101 is safe and effective when infused in patients with a hematologic malignancy following a T-cell depleted stem cell graft from a related…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02500550
- Testing
- ATIR101, Haploidentical hematopoietic stem cell transplantation (HSCT), TBI regime
- Where
- 11 sites in Belgium, Canada and 4 more
- Volunteers
- 15 people
- Sponsor
- Kiadis Pharma
BKV Infection, EBV Infection
Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.
The goal of this clinical trial is to evaluate the efficacy and safety of Multi-Virus Specific T cells (LB-DTK-MV) to treat patients diagnosed with antiviral-resistant CMV, BKV, or EBV infection or associated diseases after…
- Conditions
- BKV Infection, EBV Infection, CMV Infection
- Trial name
- NCT07670468
- Testing
- LB-DTK-MV
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- LucasBio
Neutropenia, Febrile, Hematologic Cancer
CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients
Patients with blood cancers and those who received a bone marrow transplant frequently have low circulating white blood cell countS.
- Trial name
- CEF-10 (NCT05061654)
- Testing
- Ceftolozane-tazobactam IV
- Where
- Qatar
- Sponsor
- Hamad Medical Corporation
Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
The purpose of this trial is to evaluate a CMV vaccine given to related donor/recipient pairs (donors prior to peripheral blood stem cell donation and CMV-seropositive recipients just before and after transplantation) and…
- Conditions
- Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Hodgkin's Lymphoma
- Trial name
- NCT00285259
- Testing
- VCL-CB01, Phosphate-buffered Saline (PBS)
- Where
- 22 sites in United States
- Volunteers
- 112 people
- Sponsor
- Astellas Pharma Inc
Multiple Myeloma, Non-Hodgkin Lymphoma
Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
A phase II study to evaluate the safety, pharmacokinetics, and hematopoietic stem cell mobilization of TG-0054 in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease
- Trial name
- NCT01018979
- Testing
- TG-0054 (2.24 mg/kg), TG-0054 (3.14 mg/kg)
- Where
- 6 sites in Taiwan
- Volunteers
- 19 people
- Sponsor
- GPCR Therapeutics, Inc.
Solid Tumor, Renal Cell Carcinoma (Kidney Cancer)
A Study of NDI 1150-101 in Patients With Solid Tumors
This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of NDI-101150 given as…
- Conditions
- Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05128487
- Testing
- NDI-101150, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 106 people
- Sponsor
- Nimbus Saturn, Inc.
Leukemia, Lymphoma
Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children
This is an open, single-arm, prospective，clinical study to evaluate efficacy and safety of Auto CAR-T cell injection in the treatment of recurrent or refractory Hematopoietic and Lymphoid Tissue Tumors in Children
- Trial name
- NCT04610125
- Testing
- Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
This study will evaluate patients with blood cell cancers who are going to have an allogeneic (donor) blood stem cell transplant from a partially matched relative.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT01744223
- Testing
- BPX-501 dose 1, Rimiducid, BPX-501 dose 2
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Bellicum Pharmaceuticals
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation
Study CR-AIR-006 is a part of the ATIR clinical development plan and will provide control data for patients treated with ATIR in clinical studies (e.g. study CR-AIR-007).
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02188290
- Where
- 9 sites in United States, Belgium and 4 more
- Volunteers
- 178 people
- Sponsor
- Kiadis Pharma
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).
The purpose of the study is to determine the maximal tolerated dose and schedule of CC-486, known as oral azacitidine, in patients with AML or MDS after allogeneic hematopoetic stem cell transplant (HSCT).
- Trial name
- NCT01835587
- Testing
- CC-486
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 31 people
- Sponsor
- Celgene
Malignant Lymphoma, Multiple Myeloma
A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
A randomized, comparative, double-blind trial of pentaisomaltose and dimethyl sulphoxide for cryoprotection of hematopoietic stem cells in subjects with multiple myeloma or malignant lymphoma with a need for autologous…
- Trial name
- NCT05545202
- Testing
- Pentaisomaltose
- Volunteers
- 150 people
- Sponsor
- Pharmacosmos A/S
Acute Myeloid Leukemia, Leukemia, Acute Myeloid
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus…
- Conditions
- Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute
- Trial name
- SIERRA (NCT02665065)
- Testing
- Iomab-B, Conventional Care, HCT
- Where
- 24 sites in United States, Canada
- Volunteers
- 153 people
- Sponsor
- Actinium Pharmaceuticals
Hodgkin Lymphoma, Non Hodgkin Lymphoma
A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation
High-dose chemotherapy followed by blood stem cell transplantation is administered to lymphoma patients with an intention to cure.
- Trial name
- E-CELERATE (NCT05181540)
- Testing
- AB-205
- Where
- 28 sites in United States
- Volunteers
- 130 people
- Sponsor
- Angiocrine Bioscience
Leukemia, Myeloid, Acute
A Long-term Follow-up Study of Patients Who Received VOR33
VOR33 long-term follow-up (LTFU) study
- Trial name
- NCT05309733
- Testing
- VOR33
- Where
- 11 sites in United States, Canada
- Volunteers
- 10 people
- Sponsor
- Vor Biopharma
Multiple Myeloma, Non-Hodgkin Lymphoma
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
This is a phase II study to evaluate the efficacy and safety of TG-0054 combined with G-CSF in mobilizing hematopoietic stem cells in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease
- Trial name
- NCT02104427
- Testing
- TG-0054 combined with G-CSF
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- GPCR Therapeutics, Inc.
Multiple Myeloma
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.
- Trial name
- NCT03652064
- Testing
- Daratumumab, Bortezomib, Lenalidomide
- Where
- 114 sites in United States, Brazil and 11 more
- Volunteers
- 395 people
- Sponsor
- Janssen Research & Development, LLC
Leukemia
A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT
20010133 is an open-label, dose escalation study in pediatric patients with acute leukemias receiving myelotoxic therapy (high dose etoposide, cyclophosphamide and total body irradiation [TBI]) followed by hematopoietic stem cell…
- Trial name
- NCT00460421
- Testing
- Palifermin, Total Body irradiation, Chemotherapy
- Where
- 7 sites in United States
- Volunteers
- 27 people
- Sponsor
- Swedish Orphan Biovitrum
Adult B Acute Lymphoblastic Leukemia
Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation
This is an open, single-arm, phase I/phase II clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Relapsed Refractory (R/R) adult acute lymphoblastic…
- Trial name
- NCT04626726
- Testing
- CD19 CAR-T, CD22 CAR-T, CD19+CD22 CAR-T
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
The purpose of the study is to compare overall response rate (ORR) between treatment groups in participants with higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) who are not eligible for…
- Trial name
- NCT04264806
- Testing
- Azacitidine, Cusatuzumab
- Where
- 73 sites in Australia, Brazil and 9 more
- Sponsor
- Janssen Research & Development, LLC